Max Seibold, PhD

Max Seibold
Max Seibold, PhD, is a researcher at National Jewish Health. Dr. Seibold is in the Center for Genes, Environment & Health and Office of Academic Affairs.
Wohlberg and Lambert Endowed Chair of Pharmacogenomics
Professor, Department of Pediatrics
Director, Regenerative Medicine and Genome Editing Program (REGEN)
Director, Computational Biology Program
Center for Genes, Environment & Health
University of Colorado-AMC, School of Medicine
Research AreasResearch Areas
  • Epidemiology
  • Genetics
  • Genomics
  • Molecular Genetics
  • Pulmonary Fibrosis
  • Asthma

Special Interests

The Seibold Lab is focused on identifying genetic determinants and biomarkers of complex lung diseases, including asthma and pulmonary fibrosis. Many of the genetic variants that influence development and severity of these lung diseases do so by altering molecular functions in specific lung cell types. His lab is focused on identifying dysregulated molecular functions in patient lung cells, by Nex-Generation sequencing technologies. Using patient cohorts the genetic determinants of these molecular changes are then mapped. The lab is also editing the genome of these lung cells to allow detailed mechanistic studies of disease variants and better understanding of how these genetic changes increase risk of disease development.

Education

Education
National Jewish Health, Genetics of Pulmonary Fibrosis, Laboratory of Dr. David Schwartz
University of California-San Francisco, PhD, Pharmaceutical Sciences and Pharmacogenomics
Southwestern Oklahoma State University, Chemistry

Publications

Interleukin-13 associated epithelial remodeling correlates with clinical severity in nasal polyposis.
Kotas ME, Patel NN, Cope EK, Gurrola JG 2nd, Goldberg AN, Pletcher SD, Seibold MA, Moore CM, Gordon ED.J Allergy Clin Immunol. 2023 Feb 1:S0091-6749(23)00141-0. doi: 10.1016/j.jaci.2022.12.826. Online ahead of print. PMID: 36736797 Free article.
 
Possibilities and promise: Leveraging advances in transcriptomics for clinical decision making in allergic diseases.
Moore CM, Seibold MA. J Allergy Clin Immunol. 2022 Oct;150(4):756-765. doi: 10.1016/j.jaci.2022.08.016. Epub 2022 Aug 28.PMID: 36037873 Free article. Review.
 
Genome-wide association study in minority children with asthma implicates DNAH5 in bronchodilator responsiveness.
Joo J, Mak ACY, Xiao S, Sleiman PM, Hu D, Huntsman S, Eng C, Kan M, Diwakar AR, Lasky-Su JA, Weiss ST, Sordillo JE, Wu AC, Cloutier M, Canino G, Forno E, Celedón JC, Seibold MA, Hakonarson H, Williams LK, Burchard EG, Himes BE. Sci Rep. 2022 Jul 22;12(1):12514. doi: 10.1038/s41598-022-16488-6.PMID: 35869121 Free PMC article.
 
Human Epidemiology and RespOnse to SARS-CoV-2 (HEROS): Objectives, Design and Enrollment Results of a 12-City Remote Observational Surveillance Study of Households with Children using Direct-to-Participant Methods. Fulkerson PC, Lussier SJ, Bendixsen CG, Castina SM, Gebretsadik T, Marlin JS, Russell PB, Seibold MA, Everman JL, Moore CM, Snyder BM, Thompson K, Tregoning GS, Wellford S, Arbes SJ, Bacharier LB, Calatroni A, Camargo CA, Dupont WD, Furuta GT, Gruchalla RS, Gupta RS, Hershey GK, Jackson DJ, Johnson CC, Kattan M, Liu AH, Murrison L, Oâ Connor GT, Phipatanakul W, Rivera-Spoljaric K, Rothenberg ME, Seroogy CM, Teach SJ, Zoratti EM, Togias A, Hartert TV. medRxiv. 2022 Jul 10:2022.07.09.22277457. doi: 10.1101/2022.07.09.22277457. Preprint.PMID: 35860216 Free PMC article.

Teaching & Professional Positions

Professor, 2022 – present
Associate Professor, CGEH, Department of Pediatrics, National Jewish Health 2015 - 2022
Assistant Professor, CGEH, Department of Pediatrics, National Jewish Health 2011 - 2015

Website Information

Seibold Lab

Ask a Question through MyChart

Sign in to your MyChart account to communicate with your care team, manage appointments, and more. Create an Account
 

Contact Information

  • Office: 877.225.5654

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our independent rating system, the Press Ganey Patient Satisfaction Survey. This survey is about the patient care experience and does not address crucial characteristics like medical decision-making, prescribing the best therapy, and patient outcomes.

Responses are measured on a scale of 1 to 5, with 5 being the best score. Learn more about our patient satisfaction survey.
 
 

Comments

Comments are collected in our Press Ganey Patient Satisfaction Surveys. Patients are de-identified to protect confidentiality and patient privacy. Learn more about our patient satisfaction survey.